Actavis CEO Says Health Law May Boost Generics Use
Feb. 15 (Bloomberg) -- Paul Bisaro, chief executive officer of Actavis Inc., talks about the impact of the U.S. Affordable Care Act on the pharmaceutical industry, so-called biosimilars, generic versions of biotechnology drugs, and the outlook for growth. He speaks with Mark Crumpton on Bloomberg Television's "Bottom Line." (Source: Bloomberg)
Most Recent Videos
Soylent: The Food of the Future?
56:55 - Rob Rhinehart, Soylent's chief executive officer, discusses the company's quest to disrupt the food industry. He speaks with Bloomberg's Emily Chang on "Bloomberg West." (Source: Bloomberg)